Patents by Inventor Pedro Cejas

Pedro Cejas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RSV RNA VACCINES
    Publication number: 20260151473
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.
    Type: Application
    Filed: September 30, 2025
    Publication date: June 4, 2026
    Applicant: ModernaTX, Inc
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
  • PIPERAZINE COMPOUNDS
    Publication number: 20260078097
    Abstract: The present invention relates to novel piperazine compounds, in particular, of formula (I) or formula (II). These piperazine compounds can be used, for example, in lipid nanoparticle compositions for drug delivery and cancer treatments.
    Type: Application
    Filed: September 7, 2023
    Publication date: March 19, 2026
    Inventors: Rui Zhang, Hao Li, Pedro Cejas, Ali Nahvi
  • RSV RNA vaccines
    Patent number: 12453766
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.
    Type: Grant
    Filed: January 19, 2024
    Date of Patent: October 28, 2025
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
  • ENHANCING NON-VIRAL DNA DELIVERY AND EXPRESSION
    Publication number: 20250302990
    Abstract: The present invention features method and composition that can be used to facilitate intracellular delivery of DNA to a subject. The provided methods and compositions employ a nanoparticle for intracellular DNA delivery and a type 1 interferon receptor pathway inhibitor. The type 1 interferon receptor pathway inhibitor is provided to decrease the subject's immune response that can be stimulated by the DNA.
    Type: Application
    Filed: September 7, 2023
    Publication date: October 2, 2025
    Inventors: Pedro Cejas, Matthew Walsh, Sean Armour, Rui Zhang
  • IMMUNE ENHANCEMENT AND INFECTIOUS DISEASE TREATMENT
    Publication number: 20250228928
    Abstract: The present invention features methods utilizing nanoparticles for double-stranded DNA (dsDNA). The nanoparticles are able to deliver the dsDNA intracellularly where the dsDNA can stimulate the innate immune response. Uses of the described methods include enhancing an immune response to a vaccine and infectious disease treatment.
    Type: Application
    Filed: March 31, 2023
    Publication date: July 17, 2025
    Inventors: Xavier ANGUELA, Sean ARMOUR, Pedro CEJAS, Ali NAHVI, Seoyun YUM, Rui ZHANG
  • IMMUNE ENHANCEMENT OF CANCER TREATMENT
    Publication number: 20250221932
    Abstract: The present invention features methods utilizing nanoparticles for double-stranded DNA (dsDNA). The nanoparticles are able to deliver the dsDNA intracellularly where the dsDNA can stimulate the innate immune response. The provided methods can be used to treat cancer and be utilized in combination with different types of therapeutic agents having anti-cancer activity and with cancer vaccines.
    Type: Application
    Filed: March 31, 2023
    Publication date: July 10, 2025
    Inventors: Xavier ANGUELA, Sean ARMOUR, Pedro CEJAS, Sonia GUEDAN, Ali NAHVI, Seoyun YUM, Rui ZHANG
  • Method of Enhancing Gene Therapy by Targeting cGAS-STING Pathway
    Publication number: 20240350667
    Abstract: The present invention features method and composition that can be used to facilitate intracellular delivery of DNA to a subject. The provided methods and compositions employ a nanoparticle for intracellular DNA delivery and a cytosolic DNA-sensing inhibitor. The cytosolic DNA-sensing inhibitor is provided to decrease the subject's immune response that can be stimulated by the DNA.
    Type: Application
    Filed: July 22, 2022
    Publication date: October 24, 2024
    Inventors: Xavier Anguel, Pedro Cejas, Ali Nahvi, Mustafa Yazicioglu, III, Rui Zhang
  • RSV RNA VACCINES
    Publication number: 20240299525
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.
    Type: Application
    Filed: January 19, 2024
    Publication date: September 12, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
  • RSV RNA vaccines
    Patent number: 11911453
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 27, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
  • RSV RNA VACCINES
    Publication number: 20210046173
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 18, 2021
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw